Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Academic Article uri icon

Overview

abstract

  • Non-receptor and receptor tyrosine kinases, such as Src and EGF receptor (EGFR), are major inducers of vascular endothelial growth factor (VEGF), one of the most potent mediators of angiogenesis. While tyrosine kinases signal through multiple pathways, signal transducer and activation of transcription 3 (Stat3) is a point of convergence for many of these and is constitutively activated with high frequency in a wide range of cancer cells. Here, we show that VEGF expression correlates with Stat3 activity in diverse human cancer cell lines. An activated Stat3 mutant (Stat3C) up-regulates VEGF expression and stimulates tumor angiogenesis. Stat3C-induced VEGF up-regulation is abrogated when a Stat3-binding site in the VEGF promoter is mutated. Furthermore, interrupting Stat3 signaling with dominant-negative Stat3 protein or Stat3 antisense oligonucleotide in tumor cells down-regulates VEGF expression. Consistent with an important role of Stat3 in VEGF up-regulation induced by various oncogenic tyrosine kinases, v-Src-mediated VEGF expression is inhibited when Stat3 signaling is blocked. Moreover, chromatin immunoprecipitation assays indicate that Stat3 protein binds to the VEGF promoter in vivo and mutation of a Stat3-binding site in the VEGF promoter abrogates v-Src-induced VEGF promoter activity. These studies provide evidence that the VEGF gene is regulated directly by Stat3 protein, and indicate that Stat3 represents a common molecular target for blocking angiogenesis induced by multiple signaling pathways in human cancers.

publication date

  • March 27, 2002

Research

keywords

  • DNA-Binding Proteins
  • Endothelial Growth Factors
  • Gene Expression Regulation, Neoplastic
  • Lymphokines
  • Neovascularization, Pathologic
  • Trans-Activators
  • Up-Regulation

Identity

Scopus Document Identifier

  • 85047695527

Digital Object Identifier (DOI)

  • 10.1038/sj.onc.1205260

PubMed ID

  • 11960372

Additional Document Info

volume

  • 21

issue

  • 13